Drugs for Vulvovaginal Candidiasis (VVC) Market Forecast and Trends
The global Drugs for
Vulvovaginal Candidiasis (VVC) market is anticipated to grow nearly at a CAGR
of 3.76% to reach US$ 1,006 million by 2026. The key drivers of growth are
projected to be the increase in the number of patients affected by candidiasis
infection, and high acceptance due to innovative vulvovaginal candidiasis drugs
are predicted to be major drivers of market growth over the forecast period.
Increasing consumer awareness of candidiasis and increasing number of treatment
options are major drivers of candidiasis market growth.
Moreover, factor driving the
market growth is expected to be the increasing awareness of hygiene among
people in developing countries. The drug is formulated in various forms,
including pessary, cream, and others. The increasing number of patients
affected by candidiasis infection, combined with the growing acceptance of
innovative drugs, are some of the key factors expected to stimulate demand from
the vulvovaginal candidiasis market. Globally, market players are involved in innovating
new product development, which is likely to support market growth over the
forecast period. In addition, approaches such as mergers and business behemoths
acquisitions and partnerships are possible to provide a tailwind to the
worldwide market for vulvovaginal candidiasis (VVC) drugs.
Drugs for Vulvovaginal Candidiasis (VVC) Market Overview:
Candidiasis is a form of
infection caused by yeast–candida, often known as a fungus that is found in the
human body. It is usually present in areas like the mouth, the abdomen, and the
skin. This dormant yeast can contribute to candida infection at any point in a
person's life and is closely linked to the person's level of immunity. There
are various types of infections caused by candidiasis, such as thrush /
oropharyngeal candidiasis, genital yeast infection / invasive infection, and
cutaneous candidiasis Medications for Vulvovaginal Candidiasis is a drug used
to treat vulvovaginal candidiasis. Vulvovaginal Candidiasis is also referred to
as vaginal thrush. Numerous types of drugs are available for Vulvovaginal
Candidiasis, including miconazole, clotrimazole, fluconazole, econazole, and
others. The drug is formulated in different types, including cream, pessary,
and others. An increase in the number of patients affected by candidiasis
infection and high uptake due to innovative medicines would help boost the
global market for vulvovaginal candidiasis drugs.
Rising Incidences of
Candidiasis Driving Adoption of VVC Drugs Market
The increased incidence of
VVC infections is the main contributing factor projected to fuel the growth of
the demand for VVC drugs over the forecast period. Increasing rising R&D
investment deployed by pharmaceutical manufacturers for the production of novel
antifungals, market expansion is strongly supported. Azoles are the class of
drugs most widely used to treat systemic fungal infection. These are known as
triazoles and imidazoles. Triazoles such as fluconazole, voriconazole and
itraconazole have a strong wide-spectrum action and offer higher levels of
safety compared to other therapeutic agents. The triazoles have less adverse
effects and extreme reactions between products and medicines and have enhanced
pharmocinetic properties. Completely these advantages lead to the current
azoles supremacy among other drug classes.
expenditure and the expansion of the product pipeline by pharmaceutical
manufacturers In recent years, the market for the treatment of fungal diseases
has sprouted a number of highly effective and safe antifungal agents. Some of
the most effective therapies on the market are terbinafine, itraconazole,
fluconazole. Increasing R&D expenditure and expanding the pharmaceutical
manufacturers ' advanced product pipeline for anti-infective development is one
of the key factors contributing to the growth of the antifungal drug sector.
Players focus on developing effective therapeutic agents in immunocompromised
patients to treat systemic fungal infections. Different public-private
collaboration arrangements to develop new technologies are expected to provide
tremendous growth opportunities for the sector.
Narrow Pipeline Molecules
High rates of morbidity and
mortality associated with candidiasis clearly indicate the ineffectiveness of
conventional antifungal treatment to treat candidiasis. Fungal cells are
eukaryotic, making it even more difficult to produce antifungal drugs.
Therefore, selective pathogen-specific targets for drug discovery and
development are much more difficult to identify. Clinically, the current
options available for combat candidiasis are limited to three types of
antifungal agents-polyene, azoles, and echinocandins. The availability of
herbal alternative to fungal infection can hinder market growth.
Drugs for Vulvovaginal Candidiasis (VVC) Market: Formulation Type
The Vulvovaginal Candidiasis
(VVC) Drug market, based on formulation type, segmented into Topical (Cream,
Lotion, Gel, Ointment, Aerosol, Foam, Powder, Solution etc.), Pessary
(Suppositories, Kit) and Oral (Tablet, Capsule, Powder for Suspension etc.).
Amidst the formulation type, the Topical segment will fuel the market for
Vulvovaginal Candidiasis Drugs due to rising demand from small and medium-sized
enterprises, and various industry verticals would provide enough room for
market growth over the forecast period. Topical is used to treat diseases of
vaginal yeast. This decreases vaginal pain, itching, and discharge with this
condition. This drug is an antifungal azole. It works by preventing the growth
of the infection-causing yeast (Fungus).
Drugs for Vulvovaginal Candidiasis (VVC) Market: Drug Type
The Vulvovaginal Candidiasis
(VVC) Drug market, based on Drug Type, segmented into Miconazole, Clotrimazole,
Fluconazole, Econazole, and Other (Itraconazole, Nystatin, Tioconazole,
amphotericin B Etc.). The Fluconazole drug in the Drug Type segment is widely
used for the treatment of the Vulvovaginal Candidiasis (VVC). Other treatments
may be required for infections that are more severe, that don't get better, or
that keep coming back after they get better. These include multiple doses of
fluconazole obtained by mouth or other medicines used inside the vagina, such
as boric acid, nystatin, or flucytosine. Fluconazole is a drug that is most
effective and safe. Fluconazole is also available as a generic medication. A
number of fungal and yeast infections are prevented and treated with
Drugs for Vulvovaginal Candidiasis (VVC) Market: End User
Based on End user, the
Vulvovaginal Candidiasis (VVC) Drug market segmented into the hospitals,
clinics, and Pharmacy. The hospital in the End user segment is widely used for
the treatment of the Vulvovaginal Candidiasis (VVC). Hospital is predicted to
be the fastest growing application segment on the global Vulvovaginal
Candidiasis (VVC) Drug market and its dominance over the forecast period is
expected to be maintained. Vulvovaginal Candidiasis (VVC) Drug is augmenting
due to increasing consumer inclination towards maintaining aesthetic appearance.
Increase in Number of Patients Affected by Candidiasis Infection and Increasing
consumer awareness about candidiasis and growing number of treatments driving
the hospital market.
Drugs for Vulvovaginal Candidiasis (VVC) Market: Regional insights
By geography, the global
Drugs for Vulvovaginal Candidiasis (VVC) Market segregated into North America,
Europe, Asia Pacific, Middle East & Africa, and Latin America. North
America is expected to dominate the market, due to the growing incidence of vulvovaginal
candidiasis (VVC) among the population in the region would drive the growth of
the sector. The prevalence of sedentary lifestyles has a major impact on
women's health. Changing lifestyles, particularly among the working population,
had an impact on women's health, which has contributed to these illnesses. In
addition, changes in eating habits have influenced health, especially among the
working women population.
for Vulvovaginal Candidiasis (VVC) Market: Competitive Landscape
The major market players in
the Global Drugs for Vulvovaginal Candidiasis (VVC) are Bayer, Perrigo, J &
J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical,
Kingyork Group, Janssen, Actavis, Tianjin Kingyork Group, Tianjin Pacific
Pharmaceutical, Lunan Pharmaceutical, Viamet Pharmaceuticals, and other
Prominent Players are expanding their presence in the market by implementing
various innovations and technologies.
objective of the Study:
To analyze and forecast the
global Drugs for Vulvovaginal Candidiasis (VVC) market size of the market, in
terms of value.
To examine the careful
market segmentation and forecast the market size, in terms value, based on the
region by segmenting the Global Drugs for Vulvovaginal Candidiasis (VVC) market
into five regions, namely, North America, Europe, Asia Pacific, Middle East,
South America and their leading countries.
To outline, categorized and
forecast the global Drugs for Vulvovaginal Candidiasis (VVC) market based on
the Formulation Type, Drug type, and End user.
To examine competitive
developments like technological advancement, services, and regulative framework
within the global Drugs for Vulvovaginal Candidiasis (VVC) Market.
To highlight the impact
analysis of the factors, affecting the market dynamics such as drivers,
restraints, opportunities, and challenges.
To strategically profile the
key players and comprehensively analyze their market shares along with
detailing the competitive landscape for market leaders.
of the Report
By Formulation Type
Topical (Cream, Lotion, Gel, Ointment,
Aerosol, Foam, Powder, Solution etc.)
Pessary (Suppositories, Kit)
Oral (Tablet, Capsule, Powder for Suspension
By Drug Type
Others (Itraconazole, Nystatin, Tioconazole,
amphotericin B Etc.)
By End User
Middle East & Africa
Questions answer by the report
How will the market drivers, restraints and
opportunities affect the market dynamics?
What will be the market size in terms of
value and volume and market statistics with a detailed classification?
Which segment dominates the market or region
and one will be the fastest growing and why?
A comprehensive survey of the competitive
landscape and the market participant players
Analysis of strategy adopted by the key
player and their impact on other players.
Scope for the Client
Client satisfaction is our
first and last priority and that is why BlueWeave Consulting offers
customization according to Company’s specific needs. The following
customization options are available for the report:
With five additional company detail analysis
Additional country analysis
Detailed segment analysis